急性髓系白血病 (AML) 是成人中最具侵袭性和最常见的白血病形式。金标准干预措施围绕化疗的使用，在某些情况下还包括造血干细胞移植。耐药性是治疗中常见的并发症，因为目前除了姑息治疗之外，可用于难治性 AML 的临床措施有限。本次综述的目的是重新唤起人们对利用生长激素释放激素 (GHRH) 拮抗作用治疗 AML 的新型靶向激素疗法的兴趣，因为它可能为当前治疗后完全缓解的障碍提供潜在的解决方案。概括临床前证据，GHRH 拮抗剂 (GHRH-Ant) 在体外和体内实验性人类 AML 细胞系中具有显着的抗癌活性，并且在白血病细胞系的耐药类似物中也表现出显着的癌症抑制作用。 GHRH-Ant 的作用方式与蒽环类药物正交，联合用药时可协同产生更有效的抗肿瘤作用。考虑到与标准 AML 疗法相关的不利因素以及不断出现的耐药性问题，MIA-602 代表了一种值得进一步研究的新方法。© 2024。作者。

Acute myeloid leukemia (AML) is the most aggressive and prevalent form of leukemia in adults. The gold-standard intervention revolves around the use of chemotherapy, and in some cases hematopoietic stem cell transplantation. Drug resistance is a frequent complication resulting from treatment, as it stands there are limited clinical measures available for refractory AML besides palliative care. The goal of this review is to renew interest in a novel targeted hormone therapy in the treatment of AML utilizing growth hormone-releasing hormone (GHRH) antagonism, given it may provide a potential solution for current barriers to achieving complete remission post-therapy. Recapitulating pre-clinical evidence, GHRH antagonists (GHRH-Ant) have significant anti-cancer activity across experimental human AML cell lines in vitro and in vivo and demonstrate significant inhibition of cancer in drug resistant analogs of leukemic cell lines as well. GHRH-Ant act in manners that are orthogonal to anthracyclines and when administered in combination synergize to produce a more potent anti-neoplastic effect. Considering the adversities associated with standard AML therapies and the developing issue of drug resistance, MIA-602 represents a novel approach worth further investigation.© 2024. The Author(s).